New Viral Panels
New Immunology Panels from Immunosciences Lab
Immunosciences Lab., Inc. (ISL) is a pioneer and leader in the field of clinical immunology. Licensed in California and certified by both CLIA and the College of American Pathologists, ISL was founded in 1989 and has specialised in developing unique immunological assays that has earned the lab an international reputation. The research that went into the development of these tests has been published in the most prestigious medical journals in the field. The recognition by these respected publications and the many U.S. patents awarded to Immunosciences Lab., Inc. is testimony to ISL’s over two decades of expertise and in-depth understanding of clinical immunopathology.
Lyme DiseaseBorrelia burgdorferi, the infectious agent of Lyme disease, is another known factor associated with autoimmune diseases such as Lyme arthritis and neuroborreliosis. ISL’s patented Lyme Panel B, is the most sensitive assessment for Lyme disease and other tick-borne infections. Diagnosis of Lyme disease can be difficult because its symptoms share commonalities with ALF, Alzheimer’s, autism, chronic fatigue syndrome, fibromyalgia, lupus, Parkinson’s and RA. It is crucial to combine clinical symptomatology with the most sensitive techniques available to properly diagnose Lyme disease.
-3r6fq9.png)
Viral PanelsViruses, in particular, HHV-6, are some of the major contributing factors in autoimmunity, thus, the addition of HHV-6 IgG and IgM to EBV, CMV, HSV, VZV and Measles makes ISL’s viral assessments unique. Viruses can also affect the ability of T-cells to detect antigens by cross-reaction (molecular mimicry). If viral infections remain untreated, they may result in over-activation of the immune system, which may subsequently progress to autoimmune diseases. The addition of HHV-6 IgG and IgM to EBV, CMV, HSV, VZV and Measles makes ISL’s viral assessments unique.
The simultaneous detection of biomarkers of autoimmunity along with viral or Borrelia antibodies may assist the practitioner in pinpointing the cause and effect relationship of a disease, which can help to design an effective treatment.
Available Panels:Viral Screen Essential
Biomarkers:
EBV Viral Capsid (VCA) IgGEBV Viral Capsid (VCA) IgM Cytomegalovirus (CMV) IgG Cytomegalovirus (CMV) IgMHerpes simplex Virus (HSV) 1+2 IgG Herpes simplex Virus (HSV) 1+2 IgM
Viral Screen Premier
Biomarkers:
EBV Viral Capsid (VCA) IgGEBV Viral Capsid (VCA) IgMEBV Early Antigen (EA) – D IgGEBV Nuclear Antigen (EBNA) IgG EBV Nuclear Antigen (EBNA) IgM Cytomegalovirus (CMV) IgG Cytomegalovirus (CMV) IgMHerpes simplex Virus (HSV) 1+2 IgG Herpes simplex Virus (HSV) 1+2 IgM Human Herpes Type 6 (HHV-6) IgG Human Herpes Type 6 (HHV-6) IgM Varicella zoster (VZV) IgG
Viral Screen Comprehensive
Biomarkers:
EBV Viral Capsid (VCA) IgGEBV Viral Capsid (VCA) IgMEBV Early Antigen (EA) – D IgGEBV Nuclear Antigen (EBNA) IgGEBV Nuclear Antigen (EBNA) IgMCytomegalovirus (CMV) IgG Cytomegalovirus (CMV) IgMHerpes simplex Virus (HSV) 1+2 IgGHerpes simplex Virus (HSV) 1+2 IgMHuman Herpes Type 6 (HHV-6) IgGHuman Herpes Type 6 (HHV-6) IgMVaricella zoster (VZV) IgGRubeola (Measles) IgGRubeola (Measles) IgMBV Viral Capsid (VCA) IgGEBV Viral Capsid (VCA) IgM Cytomegalovirus (CMV) IgG Cytomegalovirus (CMV) IgMHerpes simplex Virus (HSV) 1+2 IgG Herpes simplex Virus (HSV) 1+2 IgM
Immunoserology of Lyme
Biomarkers:
Borrelia burgdorferi (IgG, IgM) OspA + OspC Peptides (IgG, IgM)OspE Peptide (IgG, IgM)Leukocyte Function Associated Antigen (IgG, IgM)Immunodominant Protein (IgG, IgM)Variable Major Protein (IgG, IgM)B. b. sensu stricto (IgG, IgM)B. garinii (IgG, IgM)B. afzelii (IgG, IgM)Babesia (IgG, IgM)Ehrlichia (IgG, IgM)Bartonella (IgG, IgM)
Western Blot AssayB. burgdorferi (IgG, IgM)
Epstein Barr Virus (EBV) Panel
Biomarkers:
EBV Viral Capsid (VCA) IgG EBV Viral Capsid (VCA) IgMEBV Early Antigen (EA) – D IgG EBV Nuclear Antigen (EBNA) IgG EBV Nuclear Antigen (EBNA) IgM
Aristo Vojdani, PhD, MSc, CEO
ISL’s founder is a professor of neuroimmunology at the Carrick Institute for Graduate Studies, a faculty member in the Dept. of Preventive Medicine at Loma Linda University, and a past associate professor at the Charles Drew/UCLA School of Medicine and Science. He obtained his M.Sc. and Ph.D. in the fields of microbiology and clinical immunology with postdoctoral studies in tumor immunology at UCLA. His on-going research, spanning a 45-year career, focuses on the role of environmental triggers in complex diseases.
Professor Vojdani’s research and focus on predictive antibodies has resulted in the development of numerous antibody arrays for the detection of many autoimmune disorders. Of particular note are the arrays for autoimmune diseases that originate from the gut and manifest as attacks on the body’s own tissues or organs, including the brain. An owner of 15 US patents for laboratory assessments, Professor Vojdani has published more than 140 articles in scientific journals.
He is the CEO and Technical Director of Immunosciences Lab., Inc. in Los Angeles, CA, and sits on the editorial board of five scientific journals. In 2006, he was given the prestigious Herbert J. Rinkel Award by the American Academy of Environmental Medicine (AAEM) for excellence in teaching the techniques of environmental medicine. On November 7, 2009, he was given the Linus Pauling, PhD Award by the American College for Advancement in Medicine. And in October of 2012 he was given the F. R. Carrick Research Institute’s extremely distinguished Lifetime Achievement Award.